Equillium, Inc.
Equillium, Inc. (Nasdaq Capital Market: EQ) is a biotechnology company focused on developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's website is www.equilliumbio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Equillium, Inc. does
In the company’s own words
Equillium, Inc. (Nasdaq Capital Market: EQ) is a biotechnology company focused on developing novel therapies to treat severe autoimmune and inflammatory disorders. The company's website is www.equilliumbio.com.
Equillium operates as a clinical-stage biopharmaceutical company with a pipeline centered on two primary product candidates. EQ504 is a potent and selective aryl hydrocarbon receptor modulator designed with a multi-modal, non-immunosuppressive mechanism of action. The company initially intends to develop EQ504 for the treatment of ulcerative colitis and other gastrointestinal diseases, with potential expansion into inflammatory lung diseases. EQ302 is a first-in-class, selective bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery, being evaluated for celiac disease and other gastrointestinal indications.
The company acquired exclusive worldwide rights to EQ504 through the October 2024 acquisition of Ariagen, Inc., with potential regulatory milestone payments up to $55 million. Equillium obtained rights to EQ302 through its February 2022 acquisition of Bioniz Therapeutics, Inc., with potential regulatory milestone payments up to $5 million related to this asset.
Equillium's intellectual property portfolio comprises two main wings: a portfolio of patents directed to selective aryl hydrocarbon receptor modulators acquired through Ariagen, and a portfolio of composite peptide antagonist patents acquired through Bioniz. The AhR modulator portfolio includes four patent families with issued patents in the United States, Korea, Hong Kong, Japan, India, Mexico, and New Zealand, with expiration dates ranging from 2037 to 2047. The composite peptide portfolio includes four patent families with issued patents across multiple jurisdictions and expected expiration dates from 2032 to 2041.
The company plans to commence a Phase 1 healthy volunteer study for EQ504 in mid-2026, with data expected approximately six months thereafter. Equillium raised approximately $30 million in gross proceeds through a private placement in August 2025 and an additional $35 million in March 2026. The company believes its cash and cash equivalents will be sufficient to fund operating expenses into 2029. Equillium does not own manufacturing facilities and relies on contract manufacturing organizations for all drug substance and drug product needs.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- LA JOLLA, CA
- Fiscal year end
- December
- CIK
- 1746466
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Equillium, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Equillium, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Equillium, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Equillium, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Equillium, Inc.'s last four quarterly filings that the numbers alone won't show?”